Non Small Cell Lung Cancer Clinical Trials in Philadelphia, Pennsylvania

25 studies are recruiting for non small cell lung cancer in Philadelphia, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

    Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Clinical Study Site, Philadelphia, Pennsylvania
    Locations
    285 in total
    Run by
    Summit Therapeutics

    See if you can join NCT06767514 on ClinicalTrials.gov

  2. A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

    Researchers are looking for new ways to treat high-risk, localized non-small cell lung cancer (NSCLC) that has been removed with surgery. People with high-risk, localized NSCLC are often treated with surgery. Researchers want to learn if participants can receive 1 or 2 trial treatments to help prev…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Perelman Center for Advanced Medicine ( Site 3205), Philadelphia, Pennsylvania
    Locations
    93 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT07513376 on ClinicalTrials.gov

  3. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

    Stage
    Phase 1
    Ages
    12 and older
    Site
    Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania
    Locations
    77 in total
    Run by
    PMV Pharmaceuticals, Inc

    See if you can join NCT04585750 on ClinicalTrials.gov

  4. ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

    The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for rec…

    Stage
    Not phased
    Ages
    18 and older
    Site
    University of Pennsylvania, Philadelphia, Pennsylvania
    Locations
    57 in total
    Run by
    Guardant Health, Inc.

    See if you can join NCT05059444 on ClinicalTrials.gov

  5. A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

    The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD-L1 expression ≥ 1%

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Local Institution - 0504, Philadelphia, Pennsylvania
    Locations
    326 in total
    Run by
    Bristol-Myers Squibb

    See if you can join NCT06561386 on ClinicalTrials.gov

  6. Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

    This is a phase 3 study of pembrolizumab in combination with carboplatin/taxane (paclitaxel or nab-paclitaxel) followed by pembrolizumab with or without maintenance sacituzumab tirumotecan (sac-TMT; MK-2870) in first-line treatment of metastatic squamous non-small cell lung cancer. It is hypothesiz…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Thomas Jefferson University - Clinical Research Institute ( Site 0147), Philadelphia, Pennsylvania
    Locations
    216 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT06422143 on ClinicalTrials.gov

  7. First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

    Study STX-721-101/PFL-721CI101 is an open label, Phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (PK) exposure, and preliminary antitumor activity of STX-721/PFL-721 in participants with non-small cell lung cancer (NSCLC) carrying EGFR or HER2 exon 20 insertion (ex20ins) mutati…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Thomas Jefferson University Research Facility, Philadelphia, Pennsylvania
    Locations
    25 in total
    Run by
    Pierre Fabre Medicament

    See if you can join NCT06043817 on ClinicalTrials.gov

  8. A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer

    A study of tolododekin alfa (also known as ANK-101) administered in combination with an anti-programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) antibody in participants with advanced or metastatic non-small cell lung cancer (NSCLC). Cohort A will enroll participants who h…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Thomas Jefferson University, Philadelphia, Pennsylvania
    Locations
    11 in total
    Run by
    Ankyra Therapeutics, Inc

    See if you can join NCT07027514 on ClinicalTrials.gov

  9. FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

    This is a Phase 1 study of FT836 administered in participants with advanced solid tumors. The primary objectives of the study are to evaluate the safety and tolerability of FT836 with or without chemotherapy and/or trastuzumab or cetuximab, and to determine the recommended phase 2 dose (RP2D) of FT…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania
    Locations
    5 in total
    Run by
    Fate Therapeutics

    See if you can join NCT07216105 on ClinicalTrials.gov

  10. Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

    Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of firmonertinib at a dose level of 240 mg QD compared to investigator's choice of osimertinib (80 mg QD) or afatinib (40 mg QD) in participants who have locally advanced or metastatic NSCLC with EGFR PACC…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Fox Chase Cancer Center, Philadelphia, Pennsylvania
    Locations
    118 in total
    Run by
    ArriVent BioPharma, Inc.

    See if you can join NCT07185997 on ClinicalTrials.gov

  11. Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

    A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
    Locations
    186 in total
    Run by
    Bristol-Myers Squibb

    See if you can join NCT07100080 on ClinicalTrials.gov

  12. Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

    Phase I Study, a master protocol to investigate TCR-Engineered T cells recognizing KRAS mutations in adult subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Research Site, Philadelphia, Pennsylvania
    Locations
    18 in total
    Run by
    AstraZeneca

    See if you can join NCT06218914 on ClinicalTrials.gov

  13. A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

    The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement [N2]) non-small cell lung cancer (NSCLC). The primary hypothesis is that int…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Thomas Jefferson University - Clinical Research Institute ( Site 0006), Philadelphia, Pennsylvania
    Locations
    229 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT06077760 on ClinicalTrials.gov

  14. A Phase 1 Study of LNCB74 in Advanced Solid Tumors

    This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Sidney Kimmel Comprehensive Center at Jefferson, Philadelphia, Pennsylvania
    Locations
    14 in total
    Run by
    NextCure, Inc.

    See if you can join NCT06774963 on ClinicalTrials.gov

  15. A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)

    Researchers are investigating new treatments for untreated advanced non-small cell lung cancer (NSCLC), which is the most common form of lung cancer and lung cancer that has spread beyond surgical removal. Standard treatments include immunotherapy, such as pembrolizumab, and chemotherapy. This stud…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Abramson Cancer Center ( Site 0010), Philadelphia, Pennsylvania
    Locations
    41 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT06731907 on ClinicalTrials.gov

  16. TCR1188-ABC Cells in KRAS-mutated Cancers

    This is a Phase I, open-label dose finding study to assess the safety, manufacturing feasibility, and preliminary efficacy of TCR1188-ABC cells in patients with KRAS-mutated cancers. Initially, patients with KRAS G12V mutation positive metastatic pancreatic adenocarcinoma, cholangiocarcinoma, color…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Pennsylvania, Philadelphia, Pennsylvania
    Run by
    University of Pennsylvania

    See if you can join NCT07594067 on ClinicalTrials.gov

  17. Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

    This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a randomized study of STK-012 in combination with standard of…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Fox Chase Cancer Center, Philadelphia, Pennsylvania
    Locations
    47 in total
    Run by
    Synthekine

    See if you can join NCT05098132 on ClinicalTrials.gov

  18. Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

    This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if this approach is better or worse than the usual approach for lung cance…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
    Locations
    75 in total
    Run by
    Canadian Cancer Trials Group

    See if you can join NCT06686771 on ClinicalTrials.gov

  19. Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance

    The purpose of this study is to determine if the combination of the three anti-cancer drugs carboplatin, paclitaxel, and ramucirumab is helpful in shrinking tumors or delaying tumor growth in participants with non-small cell lung cancer. This study will also assess whether it is safe to combine the…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania
    Run by
    Abramson Cancer Center at Penn Medicine

    See if you can join NCT04332367 on ClinicalTrials.gov

  20. Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

    This is an open-label, non-randomized, single-center, phase II study to evaluate the efficacy, toxicity and, tolerability of pre-specified dose attenuated chemotherapy regimens in lung cancer patients with comorbidities.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Fox Chase Cancer Center, Philadelphia, Pennsylvania
    Run by
    Fox Chase Cancer Center

    See if you can join NCT05800587 on ClinicalTrials.gov

  21. A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

    This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Univ of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania
    Locations
    14 in total
    Run by
    Verastem, Inc.

    See if you can join NCT07020221 on ClinicalTrials.gov

  22. JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer

    To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Thomas Jefferson University, Philadelphia, Pennsylvania
    Locations
    50 in total
    Run by
    University of Texas Southwestern Medical Center

    See if you can join NCT02468024 on ClinicalTrials.gov

  23. A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

    The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose levels in participants w…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Pennsylvania, Philadelphia, Pennsylvania
    Locations
    26 in total
    Run by
    Frontier Medicines Corporation

    See if you can join NCT06244771 on ClinicalTrials.gov

  24. Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

    The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. The main questions if aims to answer are: * Does CP-383 slow or stop the growth of cancer in patients with advanced cancer * What medical prob…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Pennsylvania, Philadelphia, Pennsylvania
    Locations
    13 in total
    Run by
    Tasca Therapeutics

    See if you can join NCT07030257 on ClinicalTrials.gov

  25. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage
    Not phased
    Ages
    Any age
    Site
    Massive Bio SYNERGY-AI site, Philadelphia, Pennsylvania
    Locations
    68 in total
    Run by
    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.